Visa Chop

1000 biċċa

R-CHOP
http://www.emea.europa.eu/

CHOP
http://www.emea.europa.eu/

Company/Business Chop

76 tunnellata 940 987 1036

d. chopped fibres, staple fibres and coherent fibre blankets;

e. Whiskers, jew monokristallini jew polikristallini, ta'kwalunkwe tul;

After chopping, mix the chopped leaves thoroughly and withdraw a representative sample.

Wara t-tqattigħ, ħallat il-weraq imqatta' sewwa u ħu kampjun rappreżentattiv.

The chopped meat is transferred to a 3 litre beaker and sprinkled with 10 g of pepsin.

Il-laħam imqatta' jiġi ttrasferit għal ġo tazza biż-żennuna tat-3 litri b'10g pepsina mxerrda fuqu.

100 samples of approximately 1 g each, taken from each of the individual samples in accordance with (b), are chopped in the Moulinette blender.

100 kampjun ta' madwar 1g kull wieħed, meħuda minn kull kampjun individwali skond il-(b), jiġu mqatta' fil-blenderMoulinette.

All the leaves selected are mixed together in a plastic bag and several kilograms of them are chopped up (cutting width 0,4 to 2 mm).

Il-weraq kollha magħżula jiġu mħallta flimkien f'borża tal-plastik u ftit kilogrammi minnhom jiġu mqatta' biċċiet (wisgħa ta' tqattigħ 0,4 sa 2mm).

Kaplan Meier estimates of the median duration of event-free survival were 35 months in the R-CHOP arm compared to 13 months in the CHOP arm, representing a risk reduction of 41%.
http://www.emea.europa.eu/

L- estimi ta ’ Kaplan Meier tat- tul ta ’ żmien medju ta ’ sopravivenza mingħajr episodji kienu 35 xahar fl- R- CHOP ikkumparat mat- 13- il xahar fis- CHOP, li jirrappreżentaw tnaqqis tar- riskju ta ’ 41%.
http://www.emea.europa.eu/

At 24 months, estimates for overall survival were 68.2% in the R-CHOP arm compared to 57.4% in the CHOP arm.
http://www.emea.europa.eu/

F’ 24 xahar, l- estimi ta ’ sopravivenza ġenerali kienu ta ’ 68. 2% fl- R- CHOP ikkumparati ma ’ 57. 4% fis- CHOP.
http://www.emea.europa.eu/

A subsequent analysis of the duration of overall survival, carried out with a median follow-up duration of 60 months, confirmed the benefit of R-CHOP over CHOP treatment (p=0.0071), representing a risk reduction of 32%.
http://www.emea.europa.eu/

Analiżi sussegwenti tat- tul tas- sopravivenza globali, imwettqa b’ tul ta ’ żmien medju ta ’ wara l- kura ta ’ 60 xahar, ikkonfermat il- benefiċċju tal- kura R- CHOP fuq dik CHOP (p=0. 0071), li tirrappreżenta tnaqqis ta ’ 32%.
http://www.emea.europa.eu/

The final efficacy analysis included all randomised patients (197 CHOP, 202 R-CHOP), and had a median follow-up duration of approximately 31 months.
http://www.emea.europa.eu/

L- analiżi ta ’ l- effikaċja finali kienet tinkludi l- pazjenti meħudin b’ mod każwali kollha (197 CHOP, 202 R- CHOP), u kellha medja ta ’ tul ta ’ żmien ta ’ osservanza wara l- kura ta ’ madwar 31 xahar.
http://www.emea.europa.eu/

Although subgroups were small, MabThera maintenance treatment provided a significant benefit in terms of overall survival for both patients responding to CHOP and patients responding to R-CHOP, although longer follow-up is required to confirm this observation.
http://www.emea.europa.eu/

Għalkemm is- sottogruppi kienu żgħar, il- kura ta ’ manteniment b’ MabThera pprovdiet vantaġġ sinifikanti f’ termini ta ’ sopravivenza globali kemm għall- pazjenti li rrispondew għal CHOP kif ukoll għall- pazjenti li rrispondew għal R- CHOP, għalkemm huwa meħtieġ perijodu itwal ta ’ wara l- kura biex tiġi kkonfermata din l- osservazzjoni.
http://www.emea.europa.eu/

After a median observation time of 31 months for patients randomised to the induction phase, R-CHOP significantly improved the outcome of patients with relapsed/ refractory follicular NHL when compared to CHOP (see Table 4).
http://www.emea.europa.eu/

Wara perijodu medju ta ’ osservazzjoni ta ’ 31 xahar għall- pazjenti randomised għall- fażi ta ’ induzzjoni, R- CHOP tejbet b’ mod sinifikanti r- riżultat tal- pazjenti b’ NHL li reġgħet tfaċċat/ refrattarja meta mqabbel ma ’ CHOP (ara Tabella 4).
http://www.emea.europa.eu/

The benefit of MabThera maintenance treatment was confirmed in all subgroups analysed, regardless of induction regimen (CHOP or R-CHOP) or quality of response to induction treatment (CR or PR) (table 5).
http://www.emea.europa.eu/

Il- vantaġġ tal- kura ta ’ manteniment b’ MabThera ġie kkonfermat fis- sottogruppi kollha kkonfermati, irrispettivament mir- reġim ta ’ induzzjoni (CHOP jew R- CHOP) jew il- kwalità tar- rispons għall- kura ta ’ induzzjoni (CR jew PR) (tabella 5).
http://www.emea.europa.eu/

The analysis of all secondary parameters (response rates, progression-free survival, disease-free survival, duration of response) verified the treatment effect of R-CHOP compared to CHOP.
http://www.emea.europa.eu/

L- analiżi tal- parametri sekondarji kollha (rati tar- rispons, sopravivenza mingħajr progressjoni, sopravivenza mingħajr mard, tul taż- żmien tar- rispons) ivverifikat l- effett tal- kura ta ’ R- CHOP meta kkumparat ma ’ CHOP.
http://www.emea.europa.eu/

In a randomised, open-label trial, a total of 399 previously untreated elderly patients (age 60 to 80 years) with diffuse large B cell lymphoma received standard CHOP chemotherapy (cyclophosphamide 750 mg/ m2, doxorubicin 50 mg/ m2, vincristine 1.4 mg/ m2 up to a maximum of 2 mg on day 1, and prednisolone 40 mg/ m2/ day on days 1-5) every 3 weeks for eight cycles, or MabThera 375 mg/ m2 plus CHOP (R-CHOP).
http://www.emea.europa.eu/

Fi prova tat- tip open label magħmula b’ għażla każwali, total ta ’ 399 pazjent anzjani mhux trattati preċedentement (età bejn is- 60 u t- 80 sena) b’ limfoma taċ- ċellula B kbira mxerrda ngħataw kimoterapija CHOP standard (cyclophosphamide 750 mg/ m2, doxorubicin 50 mg/ m2, vincristine 1. 4 mg/ m2 sa massimu ta ’ 2 mg fl- ewwel ġurnata, u prednisolone 40 mg/ m2/ ġurnata fil- ġranet 1- 5) kull 3 ġimgħat għal tmien ċikli, jew MabThera 375 mg/ m2 kif ukoll CHOP (R- CHOP).
http://www.emea.europa.eu/

In all patients subgroups (gender, age, age adjusted IPI, Ann Arbor stage, ECOG, β 2 microglobulin, LDH, albumin, B symptoms, bulky disease, extranodal sites, bone marrow involvement), the risk ratios for event-free survival and overall survival (R-CHOP compared with CHOP) were less than 0.83 and 0.95 respectively.
http://www.emea.europa.eu/

Fis- sottogruppi ta ’ pazjenti kollha (sess, età, IPI aġġustat, stadju ta ’ Ann Arbor, ECOG, β2 mikroglobulina, LDH, albumin, sintomi- B, bulky disease, siti estranodali, involvement tal- mudullun), il- proporzjon tar- riskju għal sopravivenza mingħajr episodji u ta ’ sopravivenza ġenerali (R- CHOP ikkumparat ma ’ CHOP) kienu inqas minn 0. 83 u 0. 95 rispettivament.
http://www.emea.europa.eu/

Maintenance therapy In a prospective, open label, international, multi-centre, phase III trial, 465 patients with relapsed/ refractory follicular NHL were randomised in a first step to induction therapy with either CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone; n=231) or MabThera plus CHOP (R-CHOP, n=234).
http://www.emea.europa.eu/

Terapija ta ’ manteniment Fi prova prospettiva, internazzjonali, tat- tip open label, multi- ċentri, ta ’ fażi III, 465 pazjent b’ NHL follikulari li reġgħet tfaċċat/ refrattarja ntgħażlu b’ mod każwali fl- ewwel pass għal terapija ta ’ induzzjoni b’ CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone; n=231) jew MabThera flimkien ma ’ CHOP (R- CHOP, n=234).
http://www.emea.europa.eu/

This variability in V1 (27.1% and 19.0%) contributed by the range in BSA (1.53 to 2.32 m2) and concurrent CHOP therapy, respectively, were relatively small.
http://www.emea.europa.eu/

Din il- varjabilità f’ V1 (27. 1% u 19. 0%) ikkontribwita mill- firxa f’ BSA (1. 53 sa 2. 32 m2) u mit- terapija CHOP fl- istess waqt, rispettivament, kienu relattivament żgħar.
http://www.emea.europa.eu/